Welcome to our dedicated page for Agilon Health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Value-based care sounds simple—until you open Agilon Health’s latest 300-page filing and wade into risk-share tables, capitated revenue, and CMS adjustment formulas. If parsing those details feels daunting, you’re not alone.
Stock Titan turns that complexity into clarity. Our AI instantly translates every Agilon Health annual report 10-K simplified, flags shifts in medical-cost ratios inside each Agilon Health quarterly earnings report 10-Q filing, and alerts you the moment an Agilon Health 8-K material events explained hits EDGAR. Want to monitor physician-executive incentives? Real-time dashboards surface Agilon Health insider trading Form 4 transactions and send push alerts for any Agilon Health Form 4 insider transactions real-time.
Here’s what you can explore on this page:
- 10-K and 10-Q drill-downs that reveal how Agilon funds new physician groups and measures quality bonuses—understanding Agilon Health SEC documents with AI.
- Instant text and chart summaries that connect risk-adjustment revenue in 8-Ks to quarterly guidance—comprehensive Agilon Health earnings report filing analysis.
- Form 4 feeds outlining option grants and stock sales, perfect for tracking Agilon Health executive stock transactions Form 4.
- Proxy excerpts breaking down CEO compensation and partnership incentive pools—your shortcut to the latest Agilon Health proxy statement executive compensation.
Whether you’re a portfolio manager benchmarking medical-cost trend, an analyst searching for segment profitability, or a physician-investor curious about partner economics, our AI-powered summaries, expert context, and real-time updates give you the answers faster than ever. No more scrolling—just the insights that matter.
Intellia Therapeutics (NTLA) has filed a Form 4 reporting that Vice President & Chief Accounting Officer Michael P. Dube sold 2,503 shares of common stock on 07/02/2025 at $9.95 per share. The filing states this was a mandatory sell-to-cover transaction to satisfy tax-withholding obligations arising from the vesting of restricted stock units (RSUs) on 07/01/2025, rather than a discretionary sale. After the transaction, Dube continues to hold 57,137 shares directly. No derivative positions were reported.
The dollar value of the sale (≈ $25 k) is immaterial relative to Intellia’s market capitalization and daily trading volume, and the officer retains a meaningful equity stake. As such, investors are likely to view the disclosure as routine housekeeping with neutral implications for the stock’s fundamental outlook.
FAQ
What is the current stock price of Agilon Health (AGL)?
What is the market cap of Agilon Health (AGL)?
What is the core business of Agilon Health Inc?
How does Agilon Health generate its revenue?
What differentiates Agilon Health from its competitors?
How does Agilon Health support primary care physicians?
What markets and patient segments does Agilon Health serve?
How does Agilon Health ensure quality and efficiency in its operations?
